Equity
€726,909 ▲ 39.0%
DR. TINNE MESENS paid out €55,191 in dividends. That is 21% of the 2025 profit.
DR. TINNE MESENS
Lifetime
16 annual accounts with figures on one time axisGross marginpeak €401,052 (2025)
€401,052▲ 17.6%
Resultlowest -€40,516 (2017)
€259,181▲ 30.2%
Equitypeak €726,909 (2025)
€726,909▲ 39.0%
Debts
€200,745▼ 7.8%
Board1 name since 2010
1 directorMESENS Tinne
Documentsfilings and deeds
19-10-202680 days late
2025micro format
Gross margin from €341,164 to €401,052Result from €199,099 to €259,181Dividend €55,191Equity from €522,919 to €726,909Cash from €31,584 to €84,600
Key points
from the 2025 annual accountsFilings
16 annual accounts 80 days
Latest accounts filed late: after the legal deadline.
Position in the sector
€259,181
Higher net result than 93% of companies in human health. Sector median €60,088 · 20,723 companies.
Checked score
96
Excellent
Financially stronger than 69% of micro companies in human health (NACE 86)
Probability in this band: under 0.55%
Bankruptcy probability within 12 months
0.1% Very low
0%0.5%1.5%4%10%≥ 25%
The dashed line is the sector median: < 0.1% across 24,173 companies (NACE 86, micro).
Fewer than 1 in 1,000 comparable companies go bankrupt within 12 months (an estimate).
Last 24 months
12-2024: < 0.1%
01-2025: < 0.1%● unchanged vs 12-2024lowest value
02-2025: < 0.1%● unchanged vs 01-2025
03-2025: < 0.1%● unchanged vs 02-2025
04-2025: < 0.1%● unchanged vs 03-2025
05-2025: < 0.1%● unchanged vs 04-2025
06-2025: < 0.1%● unchanged vs 05-2025
07-2025: 0.1%▲ +0.1 percentage points vs 06-2025
08-2025: 0.1%● unchanged vs 07-2025
09-2025: 0.1%● unchanged vs 08-2025
10-2025: 0.2%▲ +0.1 percentage points vs 09-2025
11-2025: 0.1%▼ -0.1 percentage points vs 10-2025
12-2025: 0.1%● unchanged vs 11-2025
01-2026: 0.1%● unchanged vs 12-2025
02-2026: 0.1%● unchanged vs 01-2026
03-2026: 0.1%● unchanged vs 02-2026
04-2026: 0.1%● unchanged vs 03-2026
05-2026: 0.1%● unchanged vs 04-2026
06-2026: 0.1%● unchanged vs 05-2026
07-2026: 0.1%● unchanged vs 06-2026
08-2026: 0.3%▲ +0.2 percentage points vs 07-2026
09-2026: 0.3%● unchanged vs 08-2026highest value
10-2026: 0.1%▼ -0.2 percentage points vs 09-2026
11-2026: 0.1%● unchanged vs 10-2026
Financial strengthStrong
Score breakdown
raises risk
Last filed accounts filed 80 days late; 2 of the last 3 accounts late
lowers risk
Sector: Human health activities (NACE 86)
Figures for financial year 2025 (filed on 20-10-2026)
Size: total assets €927,653
Calculation
The band follows from the bankruptcy probability. 10 more points roughly halve it.
| 75-100 | Excellent | under 0.55% |
| 60-74 | Healthy | 0.55% to 1.5% |
| 45-59 | Fair | 1.5% to 4.2% |
| 25-44 | Weak | 4.2% to 15.0% |
| 0-24 | Critical | over 15.0% |
Where the company stands within its band depends half on the bankruptcy probability and half on how it does against its sector peers (NACE 86, micro). It does better than 82% of them on solvency, 39% on liquidity, 80% on profitability and 76% on growth.
The bankruptcy probability was computed on 04-11-2026 by the bankruptcy model of 2 October 2026, which learns from Belgian bankruptcies and reads the registers, the annual accounts and the Belgian Official Gazette.
The probability rests on the annual accounts with balance sheet date 31-12-2025.
Of the companies with a bankruptcy probability in the very low class on 30-06-2025, 0.1% went bankrupt within twelve months.
Some facts cap the score, however low the probability. With negative or zero equity, a heavy loss, a special status in the KBO, one missing filing or accounts filed more than 90 days late, the score is Fair at most (59). With two missing filings, it is Weak at most (44). During a judicial reorganisation or at the company's end (bankruptcy, dissolution, liquidation), it is Critical at most (24).
Comparable companies, two years later
In July 2024, 17,811 companies had the same profile as DR. TINNE MESENS has now. Each dot stands for 45 companies, two years later.
96.5%
were still trading
3.1%
stopped another way
0.3%
went bankrupt
That fits the bankruptcy probability of DR. TINNE MESENS itself: 0.1% within 12 months.
Test of the method
The method was tested on the 497,446 companies of July 2024. Each company was given the bankruptcy share of the same profile a year earlier, in July 2023. The expectation was that 1.6% would go bankrupt within 24 months. In fact 1.7% went bankrupt.
| Group | Expected | Actual |
|---|---|---|
| 1 | 0.2% | 0.2% |
| 2 | 0.3% | 0.5% |
| 3 | 0.5% | 0.6% |
| 4 | 0.7% | 0.8% |
| 5 | 0.9% | 0.9% |
| 6 | 1.3% | 1.5% |
| 7 | 1.6% | 1.8% |
| 8 | 1.8% | 1.8% |
| 9 | 3.0% | 3.1% |
| 10 | 5.6% | 6.2% |
A company that went bankrupt had a higher expected share than one that kept going in 74.5% of comparisons. The level depends on the economy. In a year with more bankruptcies than the year before, the actual share is higher than the expected one.
This is an observation about 17,811 companies, not a prediction for DR. TINNE MESENS. The sector does not count, because the KBO no longer lists a sector for a company that has stopped. By sector, mostly the survivors would count, which would paint too rosy a picture.
Credit verdict
Credit of up to €65,000 on 30-day terms is acceptable
Liquidity is ample, with a current ratio of 7.48 (6.12 in 2024), above the usual 1.5. Short-term debt is 10.7% and cash 9.1% of total assets. 21.6% of the assets are financed with debt and provisions.
Credit check for an amount and term of your choice
Show the recommended maximum and see how the verdict changes with amount, term and advance.
The scores and ratios are Checked's own calculations, not a credit decision.
Signals
Five signals.
lowers riskraises risk
raises risk · 2025 accounts filed 80 days late
The financial year that closed on 31-12-2025 was due by 31-07-2026 and was filed on 19-10-2026, 80 days later. Nearly half (47%) of Belgian companies file late; of those that file 1 to 90 days late, 2.0% are now bankrupt, dissolved or in another special legal status, against 1.66% of all filers. A delay like this does not count in the score.
NBB · 10 filingsDeviation from the deadline
2025
80 days late
2024
89 days late
2023
23 days late
2022
81 days late
2021
29 days late
2020
24 days early
2019
14 days early
← before the deadline
after the deadline →
tick = median of all Belgian filingsring = median in the sector
The company filed its last 7 accounts on average 38 days after the deadline. In the sector (NACE 86), the median for financial year 2024 was 7 days before the deadline, and 36% of those companies filed late.
Searched, nothing found (2)
neutral · Next filing not due yet
The next financial year closes on 31-12-2026 and is due by 31-07-2027. Nothing is late today. The company usually files around 19 October (4 of the last 5 accounts filed within 51 days either side of that date).
Companies Code · seven monthsWhere today falls in the filing period
05-11-2026 today31-12-2026 year end31-07-2027 deadline
Recent changes
Registered in the Peppol Directory
Reachable for e-invoices through 0208:0823165556
Change of role: MESENS Tinne, from manager to director
Director discharge: MESENS Tinne · General meeting of 18-08-2021 · Gazette deed
Incorporation
published on 25-02-2010 · Gazette deed
First establishment
Terboekt 119, Genk
Comparable companies
same main activity, similar in size and age| Company | Total assets | Gross margin | Solvency | Staff |
|---|---|---|---|---|
| DR. TINNE MESENS Genk | €0.9m | €401,052 | 78.4% | - |
| DR. DE CUYPER EVA Genk | €0.8m | €390,356 | 82.9% | - |
| Dr M.G. Garrino, Biologie Clinique Namur | €1.0m | €404,698 | 92.3% | - |
| Dr. Kunegonde Verbrugghe Kortrijk | €1.0m | €385,448 | 76.6% | - |
| DE CUBBER MICHAEL Mons | €0.8m | €401,067 | 33.7% | - |
| DR. K. VAN HOUDENHOVEN Bonheiden | €1.0m | €393,555 | 94.6% | - |
| Dokter DEMEDTS Ingel, Longziekten Ronse | €1.0m | €407,416 | 52.3% | - |
These companies have the same main activity as DR. TINNE MESENS: specialist medical practice (NACE 86220). They are comparable in size and age: total assets between €819,000 and €1m, founded between 2008 and 2011.
Official details
Source: KBO- Status
- Active since 12-02-2010Normal situation
- Activity
- Specialist medical practiceNACE 86220and 2 others
- Establishment unit
- 2.185.669.0293600 Genk, since 12-02-2010
- Financial year end
- 31 December
- Peppol
- Reachable since 30-05-2024
Annual accounts 2025
- Turnover
- ≈ €620,000estimated
- Total assets
- €927,653▲ 25.3%
- Filing
- Filed on 19-10-2026
Insights on DR. TINNE MESENS
DR. TINNE MESENS files the micro format. That format states no turnover. The gross margin rose from €293,646 in 2010 to €401,052 in 2025.
Sources: KBO register, filings at the National Bank, Belgian Official Gazette. Click a figure with a dotted line for the item and the filing.
Key facts about DR. TINNE MESENS
- What is the company number of DR. TINNE MESENS?
- The company number of DR. TINNE MESENS is 0823.165.556. The VAT number is the same number with BE in front: BE 0823.165.556.
- Where is DR. TINNE MESENS based?
- The registered office is at Terboekt 119, 3600 Genk.Company details
- What does DR. TINNE MESENS do?
- According to the KBO register, the main activity is specialist medical practice (NACE 86220).
- What is the legal form of DR. TINNE MESENS?
- DR. TINNE MESENS is a private limited company (BV).
- When was DR. TINNE MESENS founded?
- DR. TINNE MESENS was founded on 12-02-2010.
- Is DR. TINNE MESENS still active?
- Yes, DR. TINNE MESENS is an active enterprise in the KBO register.
- What is the turnover of DR. TINNE MESENS?
- The turnover in financial year 2025 is ≈ €620,000. This figure is estimated from the gross margin of €401,052 and 36 comparable companies (NACE 862). It probably lies between €560,000 and €780,000.Financials
- Is DR. TINNE MESENS profitable?
- In financial year 2025, DR. TINNE MESENS made a profit of €259,181.
- Where can I find the annual accounts of DR. TINNE MESENS?
- DR. TINNE MESENS filed 16 annual accounts with the National Bank of Belgium, the latest for financial year 2025.
- When are the next annual accounts of DR. TINNE MESENS due?
- DR. TINNE MESENS must file the annual accounts for financial year 2026 by 31-07-2027.Timeline
Next steps
Work out how much credit to give this customer and on what payment terms.Credit check Check what to know before you do business with this company.Supplier due diligence Check whether you can accept this company as a client under the anti-money-laundering law.AML client file Check which of your other customers you can e-invoice via Peppol.Peppol check Compare this company with its sector.Sector benchmark See what changed in the latest annual accounts.What changed
See how customers, suppliers and banks see your own company and what to improve first.